• Home
  • Search Results
  • Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC).

Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC).

PloS one (2014-04-12)
Eirini Pectasides, Theodoros Rampias, Clarence Sasaki, Christos Perisanidis, Vassilis Kouloulias, Barbara Burtness, Thomas Zaramboukas, David Rimm, George Fountzilas, Amanda Psyrri
ABSTRACT

Elucidating the molecular phenotype of cancers with high metastatic potential will facilitate the development of novel therapeutic approaches to the disease. Gene expression profiles link epithelial to mesenchymal transition (EMT) phenotype with high-risk HNSCC. We sought to determine the role of protein biomarkers of EMT in head and neck squamous carcinoma (HNSC) prognosis. Protein expression analysis of EGFR, β-catenin and E-cadherin was performed on a cohort of 102 patients with HNSCC recruited between 1992 and 2005 using automated quantitative protein analysis (AQUA). We evaluated associations with clinicopathological parameters and prognosis. There were 67 patients with primary squamous cell carcinoma of the head and neck in this cohort who met inclusion criteria and for whom we had complete E-cadherin, beta-catenin and EGFR expression data. High E-cadherin expressers had longer 5-year progression-free survival (PFS) compared to those with low E-cadherin (59.7% versus 40.6%, p = 0.04) and overall survival (OS) (69.6% versus 44.3%, p  = 0.05). Kaplan-Meier analysis showed that patients with low beta-catenin-expressing tumors trended toward worse 5-year PFS (p = 0.057). High EGFR expressers had inferior OS compared to low EGFR expressers (27.7% vs. 54%, p = 0.029). In the multivariable analysis context, E-cadherin remained an independent predictor of improved OS (HR = 0.204, 95% CI 0.043 to 0.972, p = 0.046) while EGFR trended towards significance for OS. The putative markers of EMT defined within a panel of HNSCC using AQUA are associated with tumors of poor prognosis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, clone 3F4, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-CDH1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-CDH1 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-CDH1 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, clone 67A4, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-CDH1 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-Cdh1 antibody,Mouse monoclonal, clone DCS-266, purified from hybridoma cell culture
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1172, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1170, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1180, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-CDH1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Anti-cdh1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution